Status:
UNKNOWN
Intensive Care Unit Acquired Infections in Patients Colonized With Extended Spectrum Enterobacteriaceae
Lead Sponsor:
University Hospital, Brest
Conditions:
Ventilator Associated Pneumonia
Bacteremia
Eligibility:
All Genders
18+ years
Brief Summary
Worldwide emergence of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) had become a major problem in ICU, with at least 10% of incidence at the admission in Europe. A systematic re...
Detailed Description
Intestinal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) had become a major problem in general population, morover in intensive care units. Systematic rectal swab for...
Eligibility Criteria
Inclusion
- admitted in Brest ICU (medical or surgical)
- positive rectal swab for ESBL-Enterobacteriae screening at the admission or during the ICU stay
- written consent
Exclusion
- refusing to participate
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT04903886
Start Date
June 1 2021
End Date
December 1 2021
Last Update
May 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29609